Introduction Persistent lymph node-positive disease after preoperative radiotherapy for rectal cancer is associated with adverse outcomes. We quantified mortality risks of persistent pathologic lymph nodes in lymph node-positive rectal cancer patients treated with preoperative versus postoperative chemoradiation. Methods This was a retrospective population-based analysis of 2,038 patients with stage III rectal cancer diagnosed 1994-2005 with follow-up through 2007 using data from the California Cancer Registry. Survival estimates were generated using the Kaplan-Meier method. Multivariate cancer-specific and overall mortality analyses were performed using Cox proportional hazard ratios with adjustment for age, gender, race/ethnicity, tumor grade, T stage, N stage, socioeconomic status, and time period
Introduction
Mortality rates have continued to decrease for colorectal cancer (CRC) over the past few decades, as a result of screening, early detection, and treatment advances. 1 Rectal cancer is a unique subset of CRC comprising approximately one-third of CRC cases in the USA. Modern therapy for rectal cancer is complex, involving a multidisciplinary and highly coordinated approach to care. Key advances in rectal cancer treatment include optimizing the surgical technique [total mesorectal excision (TME) is now standard of care], delivery and timing of radiation therapy, the addition of chemotherapy as a radiation sensitizer (i.e., concurrent chemoradiation), and the optimization of adjuvant chemotherapy regimens (often derived from results of adjuvant colon cancer clinical trials).
In the 1990s, adjuvant chemoradiation became the standard of care for locally advanced rectal cancer. The NIH consensus statement from 1990 states "the best current adjuvant therapy for rectal cancer involves postoperative treatment with both chemotherapy and radiotherapy. However, the absolute necessity for radiotherapy for survival benefit is by no means convincingly demonstrated at this time, and we must await the completion of current trials for clarification of this issue." 2 The shift to the routine use of preoperative chemoradiation was gradual, supported by a number of published articles including a seminal paper in 2001. 3 In that study, among locally advanced rectal cancer patients who received preoperative concurrent chemoradiation, tumor downstaging was observed in 62 % of the cases, which predicted improvement in overall survival. After a median follow-up of 36 months, the analysis demonstrated that any response to chemoradiation significantly impacted outcome, and the patients who responded to 5-fluorouracil (5FU) during preoperative chemoradiation would also predictably respond to 5FU-based adjuvant chemotherapy. In 2004, the use of preoperative concurrent chemoradiation was reported to improve local control with reduced toxicity compared to postoperative chemoradiation, but a survival benefit was not observed. 4 Today, the use of preoperative concurrent chemoradiation is the mainstay treatment for locally advanced rectal cancer. Recently, Chang et al. demonstrated that the pathologic lymph node status (ypN) after preoperative radiotherapy is a marker of prognosis. 5 Patients who are ypN+ were noted to have an increased mortality risk. 5 However, the study was limited by a lack of information on chemotherapy use-which could be a confounder for the reported observations. Here, we set out to determine if ypN+ is an adverse prognosis compared to ypN− using the California Cancer Registry (CCR) in rectal cancer patients who received therapy with chemotherapy and radiation (chemoradiation).
Materials and Methods

Study Population
Data was obtained from the CCR, California's statewide population-based cancer surveillance system and also part of the NCI SEER program. California requires all cancer cases treated in California to be reported to the CCR since 1988. 6 Cause of death according to the International Classification of Disease criteria at the time of death, and the last date of follow-up, either the date of death or the last date of contact, are reported to the CCR. 7 In 1998, the CCR developed standardized data collection and quality control procedures. 8, 9 Case reporting with follow-up has a completion rate greater than 95 % for most tumors. 10 The study only included patients with pathologically confirmed stage III rectal cancer following radical surgical resection who also received chemotherapy and radiation during their treatment course; all other stages/patients were excluded. Of rectal cancer cases, 2,038 were identified from 1994 to 2005 with follow-up until 2007. Age, sex, ethnicity/ race, socioeconomic status, histology and histologic grade, and TNM stage classification were recorded as done previously. 11 Analysis was based on preoperative and postoperative chemoradiation groups. T and N classification are defined as according to the American Joint Committee on Cancer (AJCC) rectal cancer staging.
12 N1 involved metastasis in one to three regional lymph nodes and N2 metastases in four or more regional lymph nodes.
Statistical Analysis
Cases were stratified into preoperative and postoperative chemoradiation groups. The demographic characteristics, including age, sex, ethnicity/race, SES quintile, histology, histology grade, tumor stage (T stage), and lymph node involvement, were analyzed with the χ 2 test or Fisher exact probability test for categorical variables or nonparametric one-way ANOVA for numeric variables, by preoperative and postoperative chemoradiation status. Survival curves were generated using the Kaplan-Meier method and comparisons made by log-rank tests. Multivariable Cox proportional hazards regression analyses were performed to estimate CRC-specific mortality and overall mortality for preoperative and postoperative chemoradiation groups with adjustment for age, sex, ethnicity/race, SES, histology, tumor grade, T stage, N stage, and time period of diagnosis (1994-1997, 1998-2001, and 2002-2005) . Statistical Analysis System 9.2 statistical software (SAS Institute, Cary, NC, USA) was used for all statistical analysis in the study.
Ethical Considerations
The study utilized existing data from the CCR database with no subject intervention, and no identifiers were linked to subjects. The University of California at Irvine Institutional Review Board approved this study under the category "exempt status" (Institutional Review Board no.2010-7853).
Results
Demographic Characteristics
The patients' demographic and clinical characteristics are listed in Table 1 . A total of 2,038 cases with radical surgical resection for stage III rectal cancer were identified, as shown in Fig. 1 . Thirty-two percent of cases received preoperative chemoradiation, and 67.9 % of cases received postoperative chemoradiation. In the preoperative chemoradiation group, the median age was 59 years, which was younger than the postoperative chemoradiation group (median age063 years). The majority of patients in both preoperative and postoperative chemoradiation groups were Caucasian (60.3 % and 67.3 %, respectively). African American patients represented the fewest number of patients by race/ethnicity in both groups (5.2 % and 5.3 %). Socioeconomic group was categorized into five quintiles (with first quintile the lowest). There were fewer cases in the first quintile of socioeconomic status compared with the other four quintiles. For histologic types, adenocarcinoma represented 84 % of cases, followed by mucinous adenocarcinoma, then adenocarcinoma-NOS other. The most common histologic grade was moderately differentiated, 70 %, followed by poorly differentiated, 25 %; well differentiated, 4.3 %; and undifferentiated, 0.7 %.
T and N Classification According to Chemoradiation Sequence
Only stage III rectal cancer cases were included in this study. T classification was categorized to four groups, based on AJCC criteria shown on Table 2 . In both preoperative and postoperative chemoradiation groups, 70 % of cases were identified as T3. Seventeen percent of cases are staged as T2, while T1 and T4 group had only 3 % and 10 % of cases, respectively.
Regional lymph node involvement was also based on AJCC criteria. As shown in Table 2 , in both the preoperative and postoperative chemoradiation groups, N1 (included metastasis in one to three regional lymph nodes) was observed in 49 % of total cases, and N2 (involved metastasis in four or more lymph node) was observed in 30 % of total cases, while node-positive but unspecified number of lymph nodes represented 21.2 % of the cases.
Overall and CRC-Specific Mortality
The cause of mortality was as follows for the adjuvant therapy group: 31 % due to CRC, 2.75 % due to coronary artery disease, and 5.64 % due to other causes; 53 % were alive at the end of follow-up, and 5.7 % had missing data. For the neoadjuvant therapy group, 22 % of cases died from CRC, 0.9 % due to coronary artery disease and 4.8 % due to other causes; 63 % were still alive at the end of follow-up, and 7.6 % had missing data. As seen in Fig. 2 , the 5-year overall survival rate in the preoperative chemoradiation group was significantly lower than the postoperative chemoradiation group, 50 % versus 60 % (P00.0002). The univariate HR for ypN+ (versus pN+) was 1.34 (1.15-1.56), indicating a 34 % increased risk of death from any cause in the ypN+ group. The 5-year CRC-specific survival rate in the preoperative chemoradiation group was 65 % versus 68 % (p00.32, NS) in the postoperative chemoradiation group. The univariate CRC-specific survival HR for ypN+ (versus pN+) was 1.10 (0.91-1.33). As would be expected (and as shown in Table 1 ), patients diagnosed in the early time period (1994-1997) were more likely to receive adjuvant therapy while the group diagnosed in the later period (2002) (2003) (2004) (2005) were more likely to receive neoadjuvant therapy. This resulted in higher rates of censored events in the later period, and relatively few CRC-specific events in the later time period. Additional multivariate regression analyses revealed that time period of diagnosis was largely responsible for differences between the univariate and multivariate risk estimates. In an adjusted analysis accounting for age, sex, race/ ethnicity, SES, histology, tumor grade, T stage, N stage, and time period of diagnosis, the risk of CRC-specific mortality was 78 % greater among patients with positive lymph node disease having received preoperative chemoradiation (i.e., ypN+) compared to lymph node-positive Another important difference between the two groups is that the preoperative chemoradiation treatment patients may be MMR deficient. MMR-deficient patients have limited benefit from 5FU-based chemotherapy. 13 Although this subset of patients is typically small, it is an important fact to consider.
Our findings raise the following question: how best to optimize treatment for lymph node-positive rectal cancer. One option is to be more aggressive in the preoperative period by incorporating additional chemotherapy and perhaps targeted biological agents into the radiation therapy protocol. Such potent regimens most certainly will have increased side effects and possibly result in overtreatment of patients who may have responded with 5FU/radiotherapy alone. This is especially true since some patients treated with preoperative chemoradiation will be overstaged and therefore over treated. Results from the German Rectal Cancer study showed a high number of stage 1 patients in the postoperative RT group who were felt to have stage 2-3 disease based on preoperative imaging. 4 Additionally, the problem of inconclusive staging following chemoradiation is a major limiting factor. Unfortunately, there is no consensus, and NCCN guidelines suggest either MRI or endoscopic ultrasound. In a review by Bipat et al., 14 endoscopic ultrasound of perirectal tissue invasion showed better diagnostic accuracy than that of CT and MR imaging. One problem is the endoscopic ultrasound is operator dependent and not widely available. The use of MRI is growing and in a research study by Al-Sukhni et al. 15 concluded that MRI has good accuracy for both circumferential resection margin and T staging and concluded that MRI should be considered for preoperative rectal cancer staging. Unfortunately, in our study, we could not account for the type of preoperative imaging patients received.
There have been multiple recent trials investigating XELOX (Xeloda [capecitabine]+oxaliplatin) with radiotherapy in the preoperative setting. [16] [17] [18] [19] The NSABP R-04 trial has four arms with XRT-5FU, 5FU+oxaliplatin, capecitabine, and capecitabine+oxaliplatin, and hopefully this trial will provide an answer to which regimen has better outcome when combining treatment with radiation, 19 especially relevant for patients known to have stage 3 disease.
There are numerous ongoing clinical trials incorporating more aggressive preoperative regimens. A few of the trials are employing chemotherapy combinations including oxaliplatin with 5FU 19, 20 and irinotecan with 5FU. 21 Others are incorporating targeted biologics with chemotherapy such as bevacizumab with 5FU, 22 cetuximab with 5FU, 23 panitumumab with 5FU, 24 and one trial is investigating the addition of the anti-inflammatory cyclooxygenase-2 inhibitor celecoxib with 5FU. 25 However, the role of targeted biologic therapeutics in treatment of locally advanced stage CRC has been called into question in light of recent data showing lack of efficacy in the adjuvant treatment of stage II and III colon cancer (NSABP C-08, 26 AVANT trial, 27 NCCTG-N0147). 28 The role of adjuvant chemotherapy in rectal cancer has been controversial. An earlier study by Bosset et al. 29 concluded that for rectal cancer patients receiving preoperative radiotherapy, adding 5FU-based chemotherapy preoperatively or postoperatively has no significant effect on survival. This study suggests that the benefits of chemotherapy are limited to improving local control. Furthermore, in a subsequent analysis, it was demonstrated that only patients with good prognosis (i.e., those who were down-staged to ypT0-2) benefit from adjuvant chemotherapy. The progression-free survival and overall survival curves diverged only after the poor prognosis patients (ypT3-4) had experienced treatment failure. 30 FOL-FOX (XELOX) is now used as the standard of care for the ypT3/4 N1/2 patient, [31] [32] [33] but is this enough? In addition, should a non-5FU-based regimen be used if the patient did not respond to 5FU preoperatively? Newer agents and testing of MSI, 34 thymidylate synthase, 35 ERCC-1, 36 and EGFR 37 may be implemented in future clinical trials to customize chemotherapy for the individual patient.
The timing of surgery after chemoradiation therapy is another key factor warranting consideration. Typically, rectal cancer surgery is performed 6-8 weeks after chemoradiation is completed. A trial by Habr-Gama et al. 38 demonstrated that addition of chemotherapy during the resting period after neoadjuvant chemoradiation for rectal cancer increased rates of complete tumor regression. In addition, preliminary analysis from a four-arm phase II clinical trial, 39 evaluating locally advanced rectal cancer patients treated with neoadjuvant chemoradiation followed by additional chemotherapy and delay in surgery, indicates a high pathologic complete response rate without additional complications. These preliminary results raise the question whether all patients should be treated with additional preoperative chemotherapy beyond standard preoperative concurrent chemoradiation, and also raise questions about further extending the interval between chemoradiation and surgery.
The course of radiation therapy is also evolving. The Swedish Rectal Cancer Registry conducted a retrospective analysis on short course radiation therapy. The short course of radiation was administered postoperatively, and the data revealed beneficial effects on 5-year survival, especially in patients with low tumors, and revealed a decrease in local recurrent rates. 40 Short course radiation therapy is not routinely administered in the USA, but is a treatment option that should be considered.
There are several important limitations to this study. The study is considered a retrospective study even though CCR prospectively collects the data. The change of surgical technique from 1994 to 2005 is evident by the increased use of TME. Low anterior resection with TME improves the chance of a negative circumferential resection margin (CRM) compared to blunt dissection; however, the CCR does not have patient-level information on surgical techniques employed, CRM status, or functional outcomes. The CCR dataset does not distinguish between different chemotherapy regimens, length of chemotherapy treatment, or radiation dose and duration. However, data from CCR provide information indicating which cases received chemotherapy or not, and whether radiation occurred before or after surgery. Since preoperative radiation by itself is not common, in this study, it was assumed that all patients who received radiation therapy and chemotherapy treatment prior to surgery received concurrent (as opposed to sequential) chemoradiation. The same assumption was applied to postoperative radiation group as well; all patients in the postoperative radiation group who also received chemotherapy were presumed to have received concurrent chemoradiation with or without additional adjuvant chemotherapy. Due to these limitations, we were unable to get detailed information on postoperative chemotherapy alone. Despite these limitations, CCR data provides important clinical prognostic factors for mortality after rectal cancer diagnosis, allowing for multivariate regression analysis of a large number of rectal cancer patients in a geographically contiguous region.
Conclusion
Our study evaluated the overall mortality and CRC-specific mortality of rectal cancer patients who received chemoradiation. We found that stage III rectal cancer patients having received preoperative chemoradiation represent a high-risk group, as this group had worse prognosis compared with stage III patients receiving postoperative chemoradiation. Our findings support additional clinical studies on preoperative and postoperative regimens for this high-risk patient subset.
